EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

Fast Acting, Dry Powder, Needle-Free, Intranasal Epinephrine Spray: A Promising Future Treatment for Anaphylaxis

Yuval Tal, Yaarit Ribak, Limor Rubin, Aviv Talmon, Oded Shamriz, Alon Y Hershko, Simcha Blotnick, Mohammed Bouhajib, Galia Temtsin Krayz, Carolina Abrutzky, Dalia Megiddo, Tair Lapidot und 1 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2023-10 · 11 (10) · 3047-3054

DOI: 10.1016/j.jaip.2023.06.044 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-10. Verfasst von Yuval Tal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Allergy and Clinical Immunology Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Anaphylaxis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnaphylaxisAdultHumansAdministration, IntranasalAllergensEpinephrinePowders

Stichwörter der Autor:innen

AnaphylaxisBioavailabilityEpinephrineIntranasalPowderSpray

Substanzen

AllergensEpinephrinePowders

Autor:innen und Institutionen

  • Allergy and Clinical Immunology Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Allergy and Clinical Immunology Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: oded.shamriz@mail.huji.ac.il.
  • Clinical Pharmacology Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Pharma Medica Research Inc, Bioanalytical services, Mississauga, ON, Canada.
  • Formulex Pharma Innovation Ltd, Pharmaceutical development and manufacturing, Nes Ziona, Israel.
  • Nasus Pharma, Tel Aviv, Israel.

Zitieren

APA

Tal, Y., Ribak, Y., Rubin, L., Talmon, A., Shamriz, O., Hershko, A. Y., Blotnick, S., Bouhajib, M., Krayz, G. T., Abrutzky, C., Megiddo, D., Lapidot, T., & Caraco, Y. (2023). Fast Acting, Dry Powder, Needle-Free, Intranasal Epinephrine Spray: A Promising Future Treatment for Anaphylaxis. The Journal of Allergy and Clinical Immunology: In Practice, 11(10), 3047-3054. https://doi.org/10.1016/j.jaip.2023.06.044

Vancouver

Tal Y, Ribak Y, Rubin L, Talmon A, Shamriz O, Hershko AY, et al. Fast Acting, Dry Powder, Needle-Free, Intranasal Epinephrine Spray: A Promising Future Treatment for Anaphylaxis. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(10):3047-3054. doi:10.1016/j.jaip.2023.06.044

BibTeX
@article{Tal2023,
  author = {Tal, Yuval and Ribak, Yaarit and Rubin, Limor and Talmon, Aviv and Shamriz, Oded and Hershko, Alon Y and Blotnick, Simcha and Bouhajib, Mohammed and Krayz, Galia Temtsin and Abrutzky, Carolina and Megiddo, Dalia and Lapidot, Tair and Caraco, Yoseph},
  title = {Fast Acting, Dry Powder, Needle-Free, Intranasal Epinephrine Spray: A Promising Future Treatment for Anaphylaxis},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {3047--3054},
  doi = {10.1016/j.jaip.2023.06.044}
}
Kostenlos starten →